



mpi max planck institut
informatik

The *EuResist* approach for predicting response to anti HIV-1 therapy



André Altmann

Department of Computational Biology and
applied Algorithmics

Max Planck Institute for Informatics

D-66123 Saarbrücken Germany




6th European HIV Drug Resistance Workshop
26-28.03.08, Budapest, Hungary




■ Aims of the *EuResist* project


1. Integration of clinical and virologic data from a large cohort of patients
2. Building a data-driven therapy response prediction system for guiding treatment selection




1. Integration of clinical and virologic data from a large cohort of patients




1. Integration of clinical and virologic data from a large cohort of patients



1. Integration of clinical and virologic data from a large cohort of patients




Definition of Therapy Success



- Genotype and baseline VL *at most* 90 days before therapy
- Follow-up VL at 8 [4 - 12] weeks of treatment
- Therapy successful if
 - Follow-up VL below 500 cp per ml
 - 100 fold reduction of VL



Definition of Therapy Success




- Genotype and baseline VL *at most* 90 days before therapy
- Follow-up VL at 8 [4 - 12] weeks of treatment
- Therapy successful if
 - Follow-up VL below 500 cp per ml
 - 100 fold reduction of VL

3,023 therapies met the requirements




approx. 1/3 are labeled as *failures*

2,722 used for training & 301 used for validation




2. Building a data-driven therapy response prediction system for guiding treatment selection

- The *EuResist* prediction system consists of three core prediction engines using Logistic Regression
- They work with sequence information alone (*minimal*) ...
- ... and with additional measurements and information from previous treatments or genotypes (*maximal*)




Generative Discriminative (GD) Engine


- Bayesian Network (BN) trained on 20,000 therapies (without genotypic information)
- Middle layer of the BN uses
 - Indicators for drug classes (*minimal*)
 - Number of previously used drugs from that class (*maximal*)
- Success probability predicted by the BN is a new covariate for next prediction step
- Other features:
 - Indicators for drugs / mutations
 - Mutations in past genotypes (**only maximal**)
 - Number of past treatments (**only maximal**)
 - Baseline VL (**only maximal**)



Mixed Effects (ME) Engine




Evolutionary (EV) Engine



Mixed Effects (ME) Engine

Focus on variable interactions




- mutation x mutation
- drug x drug (x drug)
- mutation x drug (x drug)

Further features are baseline VL, number of drugs in treatment, number of past treatments, vertical transmission, and NRTI experience


Large number of covariates

Model built for *maximal* feature set

Generative Discriminative (GD) Engine




Evolutionary (EV) Engine




Evolutionary (EV) Engine


- Genetic barrier is computed for every compound in the regimen
- Probability of the virus not to escape from drug pressure by developing further mutations
- Further features are:
 - Indicators for drugs / mutations
 - Interactions between drugs, mutations, or mutations and drugs
 - Indicators for previously used drugs (**maximal**)
 - Interactions between drugs and previously used drugs (**maximal**)
 - baseline VL (**maximal**)



Generative Discriminative (GD) Engine



Mixed Effects (ME) Engine




Results – single engines

Validation:


- Predicted outcome for 301 cases

Agreement among prediction engines ...

...on cases labeled as success:




...on cases labeled as failure



- Validation:
 - Predicted outcome for 301 cases
- Agreement among prediction engines ...
- 35 cases are incorrectly predicted by all three engines
- Closer analysis showed that 16 had a VL measurement below 500 cp / ml once during treatment
- In remaining 64 cases this occurred only 13 times

$p=0.011$ (Fisher's Exact)

...on cases labeled as failure





Results – single engines



Validation:

- Predicted outcome for 301 cases


Agreement among prediction engines ...



Labeled as failure



...on cases labeled as failure





Results – single engines



Validation:

- Predicted outcome for 301 cases


Agreement among prediction engines ...



Often predicted as success




...on cases labeled as failure




Results – combined engine

- Various methods for combining the prediction engines explored
- Computing the *mean* of the three predictions proved to be simple and efficient
- Variation of the training set size shows a better learning behavior of the combined engine




Results – combined engine

- Extended feature set outperforms the minimal feature set ($p=0.048$)
- Both feature sets outperform a GSS based prediction using the Stanford algorithm




- Extended feature set outperforms the minimal feature set ($p=0.048$)
- Both feature sets outperform a GSS based prediction using the Stanford algorithm
- Removal of failures with VL below 500 cp / ml once during treatment leads to an increased performance




Results – combined engine

- Extended feature set outperforms the minimal feature set ($p=0.048$)
- Both feature sets outperform a GSS based prediction using the Stanford algorithm
- Removal of failures with VL below 500 cp / ml once during treatment leads to an increased performance
- Gain is more pronounced for the *EuResist* engine than for the GSS based prediction



- Additional features like information on past treatments and baseline VL significantly improve performance
- Combination of the three engines yields a further increase in performance and robustness
- A shortcoming in the current definition of success and failure could be detected
- Despite that shortcoming the combined engine could detect the trend correctly and the used performance measure underestimated the true performance
- The *EuResist* web service will be freely available at end of June 2008



euresist Integration of viral genomics with clinical data to predict response to anti-HIV

home / **data analysis** / news / documentation / links / database Search

Viral Sequence Mutations List Xml File

Sequence

Choose one of the two methods

Text Input demo

Paste sequence text in the text below

Text File Upload

Choose a file to upload from your computer using file selection box below

Browse...

Ranking of drug combinations

10 BEST DRUG COMBINATIONS

#	Treatment	Success probability	Confidence interval	Color coding
7	3TC TDF TPV/rtv	75%	[56% - 97%]	
1	3TC TDF LPV/rtv	72%	[62% - 82%]	
4	3TC TDF FPV/rtv	70%	[54% - 86%]	
5	3TC TDF SQW/rtv	66%	[52% - 80%]	
3	3TC TDF ATV/rtv	66%	[53% - 78%]	
9	3TC AZT FPV/rtv	64%	[48% - 83%]	
6	3TC AZT SQW/rtv	62%	[50% - 74%]	
2	3TC AZT LPV/rtv	60%	[52% - 68%]	
10	3TC AZT TPV/rtv	60%	[41% - 79%]	
8	3TC AZT ATV/rtv	54%	[44% - 65%]	

YOUR PROPOSED TREATMENT

Treatment	Success probability	Confidence interval	Color coding
ddi TDF LPV/rtv	60%	[42% - 76%]	

Notes

[1] FTC is assumed to be equivalent to 3TC. However, the EuResist engine has been mainly trained with 3TC-containing regimens.